Real-World Incidence of Febrile Neutropenia Among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Sep 28

PMID 34575334

Citations 3

Authors

Yosuke Dotsu

Hiroyuki Yamaguchi

Minoru Fukuda

Takayuki Suyama

Noritaka Honda

Yasuhiro Umeyama

Hirokazu Taniguchi

Hiroshi Gyotoku

Shinnosuke Takemoto

Ryuta Tagawa

Ryosuke Ogata

Hiromi Tomono

Midori Shimada

Hiroaki Senju

Katsumi Nakatomi

Seiji Nagashima

Hiroshi Soda

Hiroaki Ikeda

Kazuto Ashizawa

Hiroshi Mukae

Affiliations

Soon will be listed here.

Abstract

Background: Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression.

Purpose: The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-agent amrubicin chemotherapy for thoracic malignancies.

Patients And Methods: The medical records of consecutive patients with thoracic malignancies, including SCLC and non-small cell lung cancer (NSCLC), who were treated with single-agent amrubicin chemotherapy in cycle 1 between January 2010 and March 2020, were retrospectively analyzed.

Results: One hundred and fifty-six patients from four institutions were enrolled. Their characteristics were as follows: median age (range): 68 (32-86); male/female: 126/30; performance status (0/1/2): 9/108/39; SCLC/NSCLC/others: 111/30/15; and prior treatment (0/1/2/3-): 1/96/31/28. One hundred and thirty-four (86%) and 97 (62%) patients experienced grade 3/4 and grade 4 neutropenia, respectively. One hundred and twelve patients (72%) required therapeutic G-CSF treatment, and 47 (30%) developed FN. Prophylactic PEG-G-CSF was not used in cycle 1 in any case. The median overall survival of the patients with FN was significantly shorter than that of the patients without FN (7.2 vs. 10.0 months, = 0.025).

Conclusions: The real-world incidence rate of FN among patients with thoracic malignancies that were treated with single-agent amrubicin chemotherapy was 30%. It is suggested that prophylactic G-CSF should be administered during the practical use of single-agent amrubicin chemotherapy for patients who have already received chemotherapy.

Citing Articles

Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics.

Das S, Samaddar S Cancers (Basel). 2025; 17(2).

PMID: 39858036 PMC: 11764476. DOI: 10.3390/cancers17020255.

Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancer.

Sekikawa M, Murakami H, Morita M, Doshita K, Miura K, Kodama H Thorac Cancer. 2023; 14(35):3475-3482.

PMID: 37873674 PMC: 10719656. DOI: 10.1111/1759-7714.15140.

Influencing factors of efficacy and long-term use of amrubicin in patients with small cell lung cancer.

Takahara Y, Tanaka T, Ishige Y, Shionoya I, Yamamura K, Sakuma T Thorac Cancer. 2023; 14(14):1286-1293.

PMID: 36994539 PMC: 10175028. DOI: 10.1111/1759-7714.14871.

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study.

Akagi K, Taniguchi H, Fukuda M, Yamazaki T, Ono S, Tomono H Thorac Cancer. 2022; 13(16):2404-2409.

PMID: 35808894 PMC: 9376170. DOI: 10.1111/1759-7714.14555.

References

Smith T, Khatcheressian J, Lyman G, Ozer H, Armitage J, Balducci L . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19):3187-205. DOI: 10.1200/JCO.2006.06.4451. View

Takemoto S, Nakamura Y, Fukuda M, Senju H, Gyotoku H, Taniguchi H . Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer. Thorac Cancer. 2017; 8(6):577-581. PMC: 5668476. DOI: 10.1111/1759-7714.12483. View

Timmer-Bonte J, De Boo T, Smit H, Biesma B, Wilschut F, Cheragwandi S . Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol. 2005; 23(31):7974-84. DOI: 10.1200/JCO.2004.00.7955. View

Igawa S, Yamamoto N, Ueda S, Ono A, Nakamura Y, Tsuya A . Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. J Thorac Oncol. 2007; 2(8):741-4. DOI: 10.1097/JTO.0b013e31811f46f0. View

Shimada M, Yamaguchi H, Fukuda M, Tomono H, Honda N, Dotsu Y . Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer. Cancer Chemother Pharmacol. 2019; 84(5):1059-1064. DOI: 10.1007/s00280-019-03940-0. View

von Pawel J, Jotte R, Spigel D, OBrien M, Socinski M, Mezger J . Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014; 32(35):4012-9. DOI: 10.1200/JCO.2013.54.5392. View

Jotte R, Conkling P, Reynolds C, Galsky M, Klein L, Fitzgibbons J . Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 2010; 29(3):287-93. DOI: 10.1200/JCO.2010.29.8851. View

Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H . Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006; 24(34):5448-53. DOI: 10.1200/JCO.2006.08.4145. View

Lyman G, Dale D, Culakova E, Poniewierski M, Wolff D, Kuderer N . The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013; 24(10):2475-2484. PMC: 3841419. DOI: 10.1093/annonc/mdt226. View

10.

Hellyer J, Gubens M, Cunanan K, Padda S, Burns M, Spittler A . Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer. 2019; 137:71-75. DOI: 10.1016/j.lungcan.2019.09.015. View

11.

Yoshida H, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N . Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol. 2011; 41(7):897-901. DOI: 10.1093/jjco/hyr065. View

12.

Ettinger D, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C . Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010; 28(15):2598-603. DOI: 10.1200/JCO.2009.26.7682. View

13.

Fukuda M, Yamaguchi H, Takemoto S, Senju H, Gyotoku H, Dotsu Y . [Trends in Outpatient Chemotherapy for Thoracic Oncology]. Gan To Kagaku Ryoho. 2020; 47(10):1461-1464. View

14.

Fukuda M, Kitazaki T, Ogawara D, Ichiki M, Mukae H, Maruyama R . Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201). Lung Cancer. 2019; 132:1-8. DOI: 10.1016/j.lungcan.2019.01.008. View

15.

Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Shimizu K, Imai H . A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer. 2009; 69(1):99-104. DOI: 10.1016/j.lungcan.2009.09.012. View

16.

Aapro M, Bohlius J, Cameron D, Dal Lago L, Donnelly J, Kearney N . 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2010; 47(1):8-32. DOI: 10.1016/j.ejca.2010.10.013. View

17.

Igawa S, Takahashi T, Nakamura Y, Tsuya A, Ono A, Shukuya T . Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens. Anticancer Res. 2009; 28(6B):3855-8. View

18.

Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M . Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Jpn J Cancer Res. 1989; 80(1):77-82. PMC: 5917682. DOI: 10.1111/j.1349-7006.1989.tb02248.x. View

19.

Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T . Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs. 1998; 16(2):121-8. DOI: 10.1023/a:1006088907271. View

20.

Abe T, Takeda K, Ohe Y, Kudoh S, Ichinose Y, Okamoto H . Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. J Clin Oncol. 2015; 33(6):575-81. DOI: 10.1200/JCO.2014.55.8627. View